SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Shares of SELLAS Life Sciences are experiencing high volatility following the circulation of third-party clinical survival models on social media that challenged the company's Phase 3 REGAL trial success probability, triggering retail panic selling and a short-term sell-off. Despite the sharp decline, bulls maintain that trial fundamentals remain unchanged and describe the action as a coordinated shakeout to capture shares from weak hands before the expected topline data announcement.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo shares are trending downward following the launch of a new $1 billion at-the-market equity offering program, which has heightened investor concerns regarding share dilution. While some traders maintain a bullish outlook on the company's long-term position in the nuclear energy sector for AI data centers, others are critical of the ongoing dilution and management's recurring share sales.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a significant stock decline triggered by mixed results from a Phase 3 study for its sonelokimab candidate in psoriatic arthritis, which failed to demonstrate clear superiority over existing therapies. Investors are expressing frustration with management's perceived lack of clear communication and recent dilutive measures, while some remain focused on the upcoming FDA filing for hidradenitis suppurativa as a primary catalyst for potential recovery.

Amplify Commodity Trust - Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF

The Breakwave Tanker Shipping ETF is experiencing significant attention due to a prolonged surge driven by escalating geopolitical tensions in the Strait of Hormuz and the Red Sea, which have caused massive disruptions to crude oil shipping routes and forced a reliance on costlier, longer paths. Traders are actively debating whether this parabolic move will continue due to structural supply chain constraints or if it faces an inevitable correction, while many note the difficulty of shorting the asset due to limited share availability and low options liquidity.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending following a fiscal fourth-quarter report that featured earnings and revenue beating analyst estimates, alongside upbeat guidance that signaled accelerating demand for optical components in AI infrastructure. Despite the strong results, the stock saw volatile price action, with some traders expressing frustration over the lack of sustained upward momentum.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

The community is debating the stock's transition from a bitcoin miner to an AI infrastructure and data center operator, with ongoing frustration over recent price volatility despite positive analyst price target upgrades and a significant long-term lease agreement. Traders are expressing skepticism about market manipulation and dilution concerns while maintaining divided views on whether to accumulate on dips or exit positions.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending as investors react to its recent outperformance against Bitcoin and other altcoins while trading in a range above $2,500. While some traders are bullish on its long-term potential for institutional adoption in tokenization and finance, others remain cautious due to broader macroeconomic uncertainty and geopolitical risks.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending as investors debate the project's long-term utility versus its history of price volatility, with many users highlighting the potential for institutional adoption through the Goliath mainnet and the integration of Chain's technology. Sentiment remains sharply divided, as some traders express frustration over consistent downward price pressure and alleged project mismanagement, while others characterize recent fluctuations as accumulation opportunities for a long-term hold.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors respond to bullish analyst reports and positive sentiment surrounding the commercial rollout of Auvelity, particularly following its FDA approval for Alzheimer's disease agitation. Market participants are focused on the drug's revenue potential and institutional backing, with many expressing optimism about long-term growth as the company shifts toward profitability.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Market sentiment surrounding MicroStrategy is driven by anticipation of the upcoming Senate vote on the Crypto Clarity Act, with traders divided between bullish expectations of a regulatory breakthrough and bearish concerns over potential dilution and macro-economic headwinds. While many see the stock as a key proxy for Bitcoin and expect institutional inflows, others remain critical of the company's capital strategy and share structure.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hims & Hers Health is currently experiencing high volatility driven by speculation regarding potential peptide product launches and broader global expansion, alongside community debate over short interest and institutional activity. Investors remain divided, with some highlighting the company's long-term growth potential and data-driven platform, while others focus on regulatory risks and intense fluctuations in trading volume.

Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC

Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing...

Hims & Hers Health, Inc. (HIMS) Securities Fraud Class Action Lawsuit Filed; November 2, 2026, Lead Plaintiff Deadline

Hims & Hers Health, Inc. (HIMS) Securities Fraud Class Action Lawsuit Filed; November 2, 2026, Lead Plaintiff Deadline Hims & Hers Health, Inc. (HIMS) Securities Fraud Class Action Lawsuit Filed; November 2, 2026, Lead Plaintiff DeadlinePR NewswireRADNOR, Pa., Sept. 11, 2026Did you buy HIMS...

HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, both dates inclusive (the Class Period), have until November 2, 2026 to seek appointment as lead plaintiff of the...

Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS

Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS PR Newswire SAN FRANCISCO, Sept. 10, 2026 SAN...

Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026 Deadline

Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026 Deadline Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026...

Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $28.17, representing a +1.66% change from its previous close.

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Here's Why Teladoc's Integrated Care Business Deserves More Attention

TDOC's Integrated Care is driving profitability as chronic care gains traction, potentially making it the company's key earnings driver.

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm PR Newswire NEW YORK, Sept. 6, 2026 NEW YORK...

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

HIMS Stock Kicks Off September In The Red: FDA’s GLP-1 Alert Steals The Spotlight From Australia Expansion 

Equity

Bearish Sentiment

Favorable

Unfavorable

Delayed

Hims & Hers ($HIMS) is bracing for a pivotal FDA advisory meeting on July 23-24 that will decide whether seven peptides get added to the compounding list. How do you think the FDA rules? Vote and explain your reasoning in the comments.

The FDA is deciding whether to add peptides to the compounding list, a ruling that could be huge for $HIMS. How do you think it goes?

Stocktwits

Hims & Hers Health Inc

The FDA is deciding whether to add peptides to the compounding list, a ruling that could be huge for 

Current Price	$27.51
Prev Close	$27.44
Open	$27.41
Dividend Yield	0.00%
50-Day Moving Average	$31.04
Beta	2.31
Avg. Volume	12.88M
PE Ratio	-44.16

52-Week High	$65.30
52-Week Low	$13.74
Market Capitalization	$6.4B
EPS (Annual)	$0.5123
Price to Book	19.80
Revenue Per Employee	$961,358.31

Feed

News

Sentiment

Earnings

Fundamentals

Info

HIMS Fundamentals